Abivax secured $920M via ADS option exercises, extending cash through 2029 to advance obefazimod in the U.S. without Big Pharma backing. A July pre-NDA FDA meeting provides a near-term catalyst amid ongoing takeover speculation, with acquisition models as high as $23B. After a volatile period related to safety signals, subsequent data aligned with expectations, helping restore investor confidence while the stock remains highly volatile.
Abivax SA announced an expanded share sale raising $800 million after strong demand, valuing the company near $11 billion. The financing eases pressure for a near-term sale and strengthens cash runway, potentially shaping strategic options and reducing immediate liquidity concerns for late-stage programs.
Abivax disclosed remission signals in harder-to-treat ulcerative colitis patients, highlighting an improved safety profile for its late-stage program. While no numeric data or timing were provided, the development could de-risk the pivotal trial and support valuation if corroborated by forthcoming top-line readouts.
Abivax said its ulcerative colitis candidate met the primary endpoint in a late-stage trial, delivering a potential regulatory catalyst for ABVX. The result may spur discussions with regulators and could prompt financing or partnering options, depending on safety data and durability of response.
Abivax plans to raise funds following the results of its maintenance trial for obefazimod, expected in late June. With a significant cash position and strong trial data, the company aims for FDA approval later this year, making it an attractive target for potential buyers. Investors are closely watching the upcoming trial readout as a pivotal event.
